EM TREATMENT OF ACUTE STROKE Progress, Problems, Politics William G. Barsan, M.D. University of Michigan.

Slides:

Advertisements

Similar presentations

Patient Recruitment Patient Recruitment Thomas Devlin, MD PhD Erlanger Southeast Regional Stroke Center.

Advertisements

3/28/2017© 2009, American Heart Association. All rights reserved.

UPDATE ON THROMBOLYTIC THERAPY Markku Kaste Department of Neurology Helsinki University Central Hospital (HUCH) University of Helsinki Markku Kaste Department.

Endovascular treatment for Small Core and Anterior circulation Proximal occlusion with Emphasis on minimizing CT to recanalization times Michael D. Hill.

Heather M. Prendergast, MD, MPH EMRA/FERNE Case Conference: Legal Issues in the ED Management of Acute Ischemic Stroke Patients.

Accomplishments in Stroke Care

TPA in Stroke: What's All the Fuss?. FERNE Brain Illness and Injury Course.

Thrombolysis for stroke in older people.

The NINDS rt-PA Stroke Trial Prior information(Pre-Clinical, Phase I Studies, etc) Thrombolytic canalization of occluded arteries may reduce the degree.

Target: Stroke Building on Success A national quality improvement initiative of the American Heart Association/American Stroke Association to improve.

Incentives for Enhancing Stroke Care Sandra M. Schneider, MD (Chair) Larry B. Goldstein, MD (Co-Chair) James G. Adams, MD Kenneth L. DeHart, M.D Michael.

Clinical Use of tPA in Acute Ischemic Stroke Edward P. Sloan, MD, MPH Associate Professor Department of Emergency Medicine University of Illinois College.

Maximizing IV Thrombolytic Therapy in Acute Ischemic Stroke Kamakshi Lakshminarayan, MD PhD Assistant Professor Neurology & Epidemiology University of.

Reducing External Barriers to Acute Stroke Care The INSTINCT Trial NIH / NINDS R01 NS

“ Remember that stroke patient you treated last night…” What to Expect following tPA Use in Acute Ischemic Stroke The INSTINCT Trial NIH / NINDS R01 NS

Anticoagulation in Acute Ischemic Stroke. TPA: Tissue Plasminogen Activator 1995: NINDS study of TPA administration Design: randomized, double blind placebo-controlled.

Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.

Brain Single-Photon Emission CT With HMPAO and Safety of Thrombolytic Therapy in Acute Ischemic Stroke Proceedings of the Meeting of the SPECT Safe Thrombolysis.

E. Bradshaw Bunney, MD Stroke Care within the 3 Hour IV tPA Window: Why IV tPA, or What Alternatives?

Andy Jagoda, MD, FACEP The Role of Emergency Medicine in Neurologic Emergencies Andy Jagoda, MD, FACEP Professor of Emergency Medicine Mount Sinai School.

Neurological Emergency Treatment Trials Network Overview of the new network William Barsan, MD PI—NETT CCC nett.umich.edu.

What can we do to cut down the time it takes to give a clot dissolving drug (tPA)?

TPA in Acute Ischemic Stroke: The NINDS Reanalysis & Meta-analysis Data Sidney Starkman, MD, FACEP.

J. Stephen Huff, MD, FACEP J. Stephen Huff, MD Associate Professor Department of Emergency Medicine University of Virginia Charlottesville, Virginia.

T-PA in Treatment of Acute Stroke: What We Know From NINDS 2004 vs 2000 Sidney Starkman, MD Departments of Emergency Medicine and Neurology, UCLA UCLA.

FERNE/MEMC Session: Treating Ischemic Stroke in the 3 – 4

Systems in Acute Stroke Care Andy Jagoda, MD Professor of Emergency Medicine Department of Emergency Medicine Mount Sinai School of Medicine New York,

Edward P. Sloan, MD, MPH FERNE/EMA Session: Treating Ischemic Stroke Patients Using a 3 to 4.5 Hour tPA Window.

Acute Ischemic Stroke Management: 2004 Emergency Medicine Perspectives.

Andy Jagoda, MD, FACEP The Upcoming ACEP Clinical Policy on ED Ischemic Stroke Patient Care: What Questions and What Implications for ED Patient Care?

Clinical Use of tPA in Acute Ischemic Stroke. Edward P. Sloan, MD, MPH Associate Professor Department of Emergency Medicine University of Illinois College.

Clinical Use of tPA in Acute Ischemic Stroke Edward P. Sloan, MD, MPH Associate Professor Department of Emergency Medicine University of Illinois College.

The potential impact of adherence to a guideline on the utilization of head CT scans in traumatic head injury patients. Frederick K. Korley M.D.

The need for trials of i.v. thrombolysis in acute ischaemic stroke 10 th January 2008.

Acute Bacterial Rhinosinusitis. Brief Background Typically follows viral infection Dx is by clinical manifestations Streptococcus pneumoniae, Haemophilus.

Interventions in Acute Ischemic Stroke: Strategies for the New Millennium For the next 25 minutes, we will spend sometime talking about Neuroimaging.

TELEMEDICINE AND RESEARCH. THE TELEICTUS PROJECT IN THE HOSPITAL St JOHN OF GOD´S OF ALJARAFE. Antonio Fernández Moyano MD. PhD. Internal Medicine Service.

The Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Brief Protocol Training NIH-NINDS U01 NS NETT CCC U01 NS NETT SDMC U01 NS

Maximizing IV Thrombolytic Therapy in Acute Ischemic Stroke Kamakshi Lakshminarayan, MD PhD Assistant Professor Neurology & Epidemiology University of.

Original Article Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke Werner Hacke, M.D., Markku Kaste, M.D., Erich Bluhmki, Ph.D., Miroslav.

10 May 2005 CASES - Original article available at CASES (Canadian Alteplase for Stroke Effectiveness Study) The CASES Investigators.

What’s on the horizon? Peter Sandercock ESC Lisbon 23rd May 2012.

Thrombolysis in acute ischaemic stroke – Updated Cochrane Thrombolysis metaanalysis JM Wardlaw, V Murray, PAG Sandercock University of Edinburgh and Karolinska.

Tissue Plasminogen Activator for Acute Ischemic Stroke National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.

Evidence in the ED Byron Drumheller, MD Penn Emergency Medicine.

Overview of new acute stroke trials Shawna Cutting, MD, MS Rush University Medical Center June 9, 2015.

Project: Ghana Emergency Medicine Collaborative

The Acute Stroke Menu: Something off the Back Page Innovative ways to use IV t-pa and other assorted therapies available outside the standard treatment.

RMH Comprehensive Stroke Centre Thrombolysis and Stroke Units : The Evidence Professor Stephen Davis Royal Melbourne Hospital Comprehensive Stroke Centre.

Acute Ischemic Stroke Treatments Patrick J. Ward, PA-S.

Mr X, 79 years old Admitted on 5/5/00 to WGH stroke unit Dense (0/5) right arm and leg paresis Aphasic CT scan excluded a bleed Given trial treatment (IST-3)

The Use of tPA in Acute Ischemic Stroke Edward P. Sloan, MD, MPH Professor Department of Emergency Medicine University of Illinois College of Medicine.

Can patients be too mild, too severe or too old for thrombolysis? Professor Peter Sandercock University of Edinburgh ESC Hamburg 27 th May 2011 Disclosures.

Stroke : To Lyse or Not to Lyse ? Understand the Literature and Decide : What is best for your practice environment ?

Richard Shih, MD, FACEP Stroke Patient Management Using IV tPA: When and How Should It Be Utilized in ED Patients?

Clinical Use of tPA in Acute Ischemic Stroke Edward P. Sloan, MD, MPH Associate Professor Department of Emergency Medicine University of Illinois College.

IST-3, SITS MOST ECASS-3 & DEFUSE Professor Peter Sandercock University of Edinburgh, UK ESC May 30 th 2007 Glasgow Competing interests:

Kim, Sun-Yong, M.D. Department of Radiology Ajou University Hospital, Suwon, Korea AGGRESIVE MECHANICAL CLOT DISRUPTION FOR ACUTE ISCHEMIC STROKE WITH.

11 WAYS TO DECREASE DOOR TO NEEDLE TIME YOU CAN DO IT FASTER Jeff Nickel, MD FACEP ED Medical Director Parkview Regional Medical Center.

Sanaz Sakiani, MD Endocrinology Fellow Journal Club

ACUTE STROKE TREATMENT: An introduction Dec.2014

Table 1: Table 2: Non Therapeutic Angiograms in Acute Ischemic Stroke Patients Being Considered for Endovascular Treatment Does not Adversely Affect Patient.

Clinical Audit of Head CT in Stroke Alert Cases: Role of Radiology Resident and CT Technologist Awareness in improving Head CT reporting time K Hooda,

Acute Stroke Therapy with IV Thrombolysis Lawrence R. Wechsler, M.D.

When Not to Intervene in Acute Stroke or

Mechanical thrombectomy

Extended Window Thrombectomy

Update from education committee

Update from education committee

Three outcome measures from the NINDS tPA trial

Presentation transcript:

EM TREATMENT OF ACUTE STROKE Progress, Problems, Politics William G. Barsan, M.D. University of Michigan

Dec NINDS t-PA trial publication Dec NINDS Symposium on Acute Stroke Dec nd NINDS Symposium Only 2% of acute strokes Rx’d following t-PA William G. Barsan, M.D.

WHAT’S THE EVIDENCE? NINDS trial Other trials

NINDS t-PA Stroke Trial Results – Part 2

NINDS t-PA Stroke Trial: Safety Results – Parts 1&2

rt-PA Benefit Graph William G. Barsan, M.D.

IS THERE BENEFIT AFTER 3 HOURS? A Pooled Analysis of the ATLANTIS, ECASS, and NINDS rtPA Stroke Trials The ATLANTIS, ECASS, and NINDS Study Group Investigators William G. Barsan, M.D.

Methods Original individual patient data were pooled from 6 randomized controlled trials Method differs from meta-analysis where individual patient data are not generally available and limited adjustment for co-variates is possible

William G. Barsan, M.D. Results 2776 patients Over 300 hospitals 18 countries Median age 68 years Median baseline NIHSSS 12

Global Outcome (mRS 0-1, BI , NIHH 0-1) at Day 90 Adjusted odds ratio with 95% confidence interval by stroke onset to treatment time (OTT) ITT population (N=2776)

rt-PA Benefit Graph William G. Barsan, M.D.

Results Odds Ratios for Favorable Outcome TimeOdds Ratio 95% Conf. Interval

William G. Barsan, M.D. WHAT’S THE PROBLEM? Knowledge gaps Teamwork issues Potential for harm Patient selection

William G. Barsan, M.D. KNOWLEDGE GAPS Many EM programs have no formal neuro rotation Lack of familiarity with measurement tools No formal training in CT interpretations Question of EP’s ability to dx stroke

William G. Barsan, M.D. EP ABILITY TO Dx STROKE Variable reports Kothari % sensitivity, 98.6% specificity Allder /70 patients misdiagnosed (UK) Libman % stroke “mimics”

William G. Barsan, M.D. TEAMWORK ISSUES EMS Neurology support Radiology support Institutional support

William G. Barsan, M.D. NEUROLOGY <50% neurologists treating with t-PA Significant number are skeptical Lack of reimbursement Lack of neurologists

William G. Barsan, M.D. RADIOLOGY Who can interpret CT’s? Availability of radiology interps What about early hypodensity? ECASS data Schriger study

William G. Barsan, M.D. INSTITUTIONAL SUPPORT Lose money on stroke DRG No reimbursement for t-PA No verification process for stroke centers ED’s are overcrowded

William G. Barsan, M.D. POTENTIAL FOR HARM NINDS - 1/17 chance of ICH 10x incidence as placebo No difference in mortality Primum non nocere

Symptomatic Intracerebral Hemorrhage Rates Glenn D. Graham 2002 William G. Barsan, M.D.

PATIENT SELECTION Few patients eligible for Rx MD’s have limited experiential knowledge Limited numbers lead to feelings of futility What about mild strokes? (Canadian data)

William G. Barsan, M.D. POLITICS EP’s are “in the hot seat” Patients expectations vs. reality Lack of support from others Concerns about litigation

William G. Barsan, M.D. POLITICS ACEP AAEM CAEP

William G. Barsan, M.D. ACEP “IV t-PA may be an efficacious therapy.” “There is insufficient evidence to endorse the use of t-PA....when systems are not in place to ensure that....NINDS guidelines....are followed.” “Decision to use t-PA....should begin at the institutional level.”

AAEM and ACEP Question tPA for Stroke

William G. Barsan, M.D. AAEM Commentary “We are aware of lawsuits against EP’s.” “This statement should assist in such matters.” “The Board’s primary constituency, the EP at the bedside has not been convinced by those promoting this therapy.” “There needs to be recognition that the circumstances....resources....cannot be easily duplicated by the average center.”

William G. Barsan, M.D. AAEM Efficacy concerns 0-90 patients skewed results Differences in stroke severity between t-PA and placebo Safety concerns Applicability concerns mimics CT interp

William G. Barsan, M.D. AAEM “Objective evidence....insufficient to warrant classification as standard of care.” “Physicians advised to use their discretion.”

William G. Barsan, M.D. 1. “Only radiologists or neurologists....should provide interpretations of CT scans.” CAEP RECOMMENDATIONS Based on data from ECASS, Schriger

William G. Barsan, M.D. CAEP RECOMMENDATIONS 2. “Stroke thrombolysis....limited to centers with appropriate....resources. Emergency physicians....should not be primary decision makers. Neurologists should be directly involved.” Concerns about EP ability to make diagnosis

William G. Barsan, M.D. CAEP RECOMMENDATIONS 3. “Administration of thrombolytic agents....should be carried out only in the setting of an approved research protocol or formal clinical practice protocol.” Concern about protocol violations Cleveland data

William G. Barsan, M.D. WHERE DO WE GO FROM HERE? Validation of data from NINDS in process need for further study? Recognition that early treatment is beneficial Implementation of recommendations from 2002 NINDS Symposium Further efforts to improve safety Establish the time limits of efficacy Investigate the role of interventional treatments

Questions?